Harvard Bioscience (HBIO) Inventory (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Inventory data on file, last reported at $22.2 million in Q1 2026.

• Inventory for Q1 2026 came in at $22.2 million, down 2.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.2 million (down 2.68% YoY), and the FY2025 annual result was $20.8 million, down 10.5% from the prior year.
• Inventory improved to $22.2 million in Q1 2026 per HBIO's latest filing, from $20.8 million in the prior quarter.
• Over five years, Inventory peaked at $29.3 million in Q2 2022 and troughed at $20.8 million in Q4 2025.
• A 5-year average of $24.8 million and a median of $25.1 million in 2024 frame the typical range for Inventory.
• The sharpest annual moves came in 2022 and 2025: Inventory rose 26.61% in 2022, then declined 16.88% in 2025.
• A 5-year view of Inventory shows it stood at $26.4 million in 2022, then retreated by 6.52% to $24.7 million in 2023, then declined by 5.95% to $23.2 million in 2024, then slipped by 10.5% to $20.8 million in 2025, then advanced by 6.73% to $22.2 million in 2026.
• Business Quant data shows HBIO's Inventory at $22.2 million in Q1 2026, $20.8 million in Q4 2025, and $21.6 million in Q3 2025.